Skip to main content
Toggle navigation
Login
Search
Home
Program Book
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Industry Encore
Home
Industry Encore
Industry Encore
Type here to filter the list
(301) Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Update from the pivotal phase 1/2 TRIDENT-1 trial
Favorite
(301) Results of a second, prespecified analysis of the Phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with extended follow-up
Favorite
(302) Efficacy and safety of first-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: an indirect treatment comparison using patient-level data from RELATIVITY-047 and CheckMate 067
Favorite
(303) Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649
Favorite
(304) Tarlatamab for Patients With Previously Treated Small Cell Lung Cancer (SCLC): Primary Analysis of the Phase 2 DeLLphi-301 Study
Favorite
(305) Durable Continuous Transfusion Independence With Imetelstat in IMerge Phase 3 for Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to or Ineligible for Erythropoiesis-Stimulating Agents
Favorite
(306) VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP
Favorite
(307) ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
Favorite
(308) IMscin001 Part 2 updated results: Efficacy, safety, immunogenicity, healthcare provider perspectives and patient-reported outcomes from the randomised Phase III study of atezolizumab subcutaneous vs intravenous in patients with locally advanced or metastatic non-small-cell lung cancer
Favorite
(309) Outcomes for Patients With Advanced Endometrial Cancer Who Completed Pembrolizumab and Continued Lenvatinib in the Phase 3 Study 309/KEYNOTE-775
Favorite
(310) Tumor Response by Baseline Metastases in Patients With Renal Cell Carcinoma Treated with Lenvatinib Plus Pembrolizumab vs Sunitinib: Post Hoc Analysis of the CLEAR Trial
Favorite
(311) Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR+/HER2– advanced breast cancer: Characterization and management of frequent adverse events from the Phase 3 CAPItello-291 trial
Favorite
(312) TROPION Lung01
Favorite
(313) TROPION Breast01
Favorite
(314) HERTHENA Lung01
Favorite
(315) Final Results of a Phase 1b Study of Subcutaneous Isatuximab Administration by an On-Body Delivery System (OBDS) Plus Pomalidomide and Dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
Favorite
(316) The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients With Relapsed/Refractory Multiple Myeloma
Favorite
(317) Tepotinib and Capmatinib in Patients with MET Exon 14 Skipping NSCLC: A Matching-Adjusted Indirect Comparison (MAIC)
Favorite
(318) Healthcare resource utilization (HCRU) and costs in patients with metastatic urothelial cancer (mUC) who received first-line (1L) treatment: results from IMPACT UC II
Favorite
(319) Healthcare costs associated with first-line treatment of patients with locally advanced or metastatic urothelial carcinoma in the United States
Favorite
(320) Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-Up and Subgroup Analysis with/without Prior BCL2i from the Phase 1/2 BRUIN Study
Favorite
(321) Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC
Favorite
(322) Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
Favorite
(323) Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: an analysis of the phase III SUNLIGHT trial
Favorite
(324) Futibatinib in Patients With FGFR2-Rearranged Intrahepatic Cholangiocarcinoma: Responder Analyses of Efficacy and Safety From the Phase 2 FOENIX-CCA2 Study
Favorite
(325) Pharmacokinetics and pharmacodynamics of proposed denosumab biosimilar and reference denosumab in healthy male subjects
Favorite
(326) Glucarpidase for Treating Adults with Delayed Methotrexate Elimination due to Impaired Renal Function: An Economic Simulation Analysis of Early versus Delayed Use.
Favorite
(327) MTXPK.org as a Clinical Decision Support Tool: Updates to the Pharmacokinetic Model and User Interface Improvements.
Favorite
(328) Elacestrant (ELA) vs standard-of-care (SOC) in ER+/HER2- advanced (adv) or metastatic breast cancer (mBC) with ESR1 mutation (ESR1-mut): key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial
Favorite
(329) Estimating the Direct and Indirect Resource Burden of Treatment Management with Current Standard of Care or Elacestrant for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population-Level Provider Model
Favorite
(330) Ibrutinib Dose Modifications for Management of Cardiac Adverse Events in Patients With B-Cell Malignancies: Pooled Analysis of 10 Clinical Trials
Favorite
(331) Administration of Ibrutinib Oral Suspension Via Nasogastric and Gastrostomy Tubes
Favorite
(332) Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study
Favorite
(333) Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study
Favorite
(334) Final Overall Survival Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan in Patients With Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer
Favorite
(335) Real-World Use Patterns, Effectiveness, and Tolerability of Sacituzumab Govitecan for Second-Line or Later Treatment of Metastatic Triple-Negative Breast Cancer
Favorite
(336) Cemiplimab plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer (phase 3 EMPOWER-Lung 3 Part 2 trial): 2-year follow-up data
Favorite
(338) Patterns of response to 200 mg linvoseltamab in patients with relapsed/refractory multiple myeloma: Longer follow-up of the LINKER-MM1 study
Favorite
(339) Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the EPCORE NHL-1 Follicular Lymphoma Dose-Expansion Cohort
Favorite
(340) Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of EPCORE NHL-1
Favorite
(341) Safety of Dostarlimab in Combination With Chemotherapy in Patients With Primary Advanced or Recurrent Endometrial Cancer in a Phase 3, Randomized, Placebo-Controlled Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Favorite
(342) Real-world Use of Niraparib Monotherapy as First-Line Switch Maintenance Therapy Following Chemotherapy Plus Bevacizumab First-Line Treatment in Patients With Epithelial Ovarian Cancer in the SW1TCH Study
Favorite
(343) Real-World Time to Treatment Discontinuation of First-Line Maintenance Niraparib Monotherapy in Epithelial Ovarian Cancer: CHAR1ZMA Study
Favorite
(344) Quality-Adjusted Time Without Symptoms of Disease or Toxicity in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel in the ENGOT-EN6/GOG-3031/RUBY Trial
Favorite
(345) Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib in the Phase 3 SIMPLIFY-1 and MOMENTUM Trials
Favorite
(346) Clinical Effectiveness and Safety of Momelotinib Compared With Continued Ruxolitinib or Best Available Therapy in Patients WithMyelofibrosis Who Required Red Blood Cell Transfusions: Subgroup Analysis of the Phase 3 SIMPLIFY-2 Study
Favorite
(347) Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration
Favorite
(348) Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
Favorite
(349) Cutaneous Toxicities With Amivantamab for Non–Small Cell Lung Cancer (NSCLC) With Exon 20 Insertion Mutation (ex20ins): A Practical Guide and Best Practices for Management
Favorite
(350) Ibrutinib Dose Adjustment Does not Impact Time to Next Treatment in First-Line Patients With Chronic Lymphocytic Leukemia: a Real-World Analysis of Electronic Medical Records From Academic and Non-Teaching Hospitals Using Target Trial Emulation
Favorite
(351) Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study
Favorite
(352) Efficacy and Safety in Patients With Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel as Study Treatment in the Phase 3 CARTITUDE-4 Trial
Favorite
(353) Talazoparib Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: Safety Analyses From the Randomized, Placebo-Controlled, Phase 3 TALAPRO-2 Study
Favorite
(354) Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnestimm Studies
Favorite
(355) Efficacy of elranatamab and teclistamab in triple-class exposed/refractory multiple myeloma (TCE/R MM): A matching-adjusted indirect comparison (MAIC)
Favorite
(356) Clinical Factors Associated with Cytokine Release Syndrome (CRS) and Elranatamab (ELRA) Dosing Recommendations After a Dose Interruption (DI)
Favorite
(357) Elranatamab monotherapy in patients with relapsed or refractory multiple myeloma: updated long-term efficacy and safety from MagnetisMM-3
Favorite
(358) Exposure-Safety Analyses of Talazoparib in Combination With Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in TALAPRO-2 Trial
Favorite
(359) PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHO RECEIVE TRILACICLIB PRIOR TO CYTOTOXIC CHEMOTHERAPY EXHIBIT IMPROVED SURVIVALAFTER RECEIVING SUBSEQUENT ANTICANCER THERAPY
Favorite
(360) ASSESSMENT OF HOSPITALIZATIONS AND CYTOPENIA EVENTS AMONG PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) RECEIVING CHEMOTHERAPY WITH TRILACICLIB
Favorite
(361) MYELOSUPPRESSION AND HEALTHCARE UTILIZATION AMONG PATIENTS WITH CHEMOTHERAPY-TREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) WITH AND WITHOUT TRILACICLIB FROM COMMUNITY ONCOLOGY PRACTICES
Favorite
(362) BURDEN OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION ON PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) FROM THE PERSPECTIVE OF PATIENTS AND CAREGIVERS
Favorite
(363) Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Trial: Mirvetuximab Soravtansine (MIRV) Prolongs Overall Survival vs Investigator’s Choice Chemotherapy (IC) in Platinum-Resistant Ovarian Cancer (PROC) With High Folate Receptor-Alpha (FRalpha) Expression
Favorite
(364) Health-Related Quality of Life in Patients with FRalpha-Positive Platinum-Resistant Ovarian Cancer Treated With Mirvetuximab Soravtansine vs Investigator’s Choice Chemotherapy: Analysis From the Phase 3 MIRASOL Trial
Favorite